BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 24855562)

  • 1. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy.
    Schaer DA; Hirschhorn-Cymerman D; Wolchok JD
    J Immunother Cancer; 2014; 2():7. PubMed ID: 24855562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
    Moran AE; Kovacsovics-Bankowski M; Weinberg AD
    Curr Opin Immunol; 2013 Apr; 25(2):230-7. PubMed ID: 23414607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contextual role of TNFR family members in CD8(+) T-cell control of viral infections.
    Wortzman ME; Clouthier DL; McPherson AJ; Lin GH; Watts TH
    Immunol Rev; 2013 Sep; 255(1):125-48. PubMed ID: 23947352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
    Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
    Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR.
    Mizuno R; Maruhashi T; Sugiura D; Shimizu K; Watada M; Okazaki IM; Okazaki T
    Biochem Biophys Res Commun; 2019 Apr; 511(3):491-497. PubMed ID: 30771904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
    Waight JD; Gombos RB; Wilson NS
    Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.
    Mascarelli DE; Rosa RSM; Toscaro JM; Semionatto IF; Ruas LP; Fogagnolo CT; Lima GC; Bajgelman MC
    Front Cell Dev Biol; 2021; 9():692982. PubMed ID: 34277638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
    Sanmamed MF; Pastor F; Rodriguez A; Perez-Gracia JL; Rodriguez-Ruiz ME; Jure-Kunkel M; Melero I
    Semin Oncol; 2015 Aug; 42(4):640-55. PubMed ID: 26320067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonist antibodies to TNFR molecules that costimulate T and NK cells.
    Melero I; Hirschhorn-Cymerman D; Morales-Kastresana A; Sanmamed MF; Wolchok JD
    Clin Cancer Res; 2013 Mar; 19(5):1044-53. PubMed ID: 23460535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TNF-TNFR Family of Co-signal Molecules.
    So T; Ishii N
    Adv Exp Med Biol; 2019; 1189():53-84. PubMed ID: 31758531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of CTLA-4 and GITR for cancer immunotherapy.
    Avogadri F; Yuan J; Yang A; Schaer D; Wolchok JD
    Curr Top Microbiol Immunol; 2011; 344():211-44. PubMed ID: 20563707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Thalidomide on the Expression of OX40, 4-1BB, and GITR in T Cell Subsets.
    Kim BS; Kim JY; Kim EJ; Lee JG; Joo DJ; Huh KH; Kim MS; Kim YS
    Transplant Proc; 2016 May; 48(4):1270-4. PubMed ID: 27320601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Targets of Immunotherapy in Gynecologic Cancer.
    Cheng H; Zong L; Kong Y; Gu Y; Yang J; Xiang Y
    Onco Targets Ther; 2020; 13():11869-11882. PubMed ID: 33239889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity.
    He Y; Vlaming M; van Meerten T; Bremer E
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New emerging targets in cancer immunotherapy: the role of GITR.
    Buzzatti G; Dellepiane C; Del Mastro L
    ESMO Open; 2020 Aug; 4(Suppl 3):e000738. PubMed ID: 32817129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF/TNFR family members in costimulation of T cell responses.
    Watts TH
    Annu Rev Immunol; 2005; 23():23-68. PubMed ID: 15771565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
    Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
    Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
    [No Abstract]   [Full Text] [Related]  

  • 18. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
    Croft M
    Nat Rev Immunol; 2003 Aug; 3(8):609-20. PubMed ID: 12974476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TNF family in T cell differentiation and function--unanswered questions and future directions.
    Croft M
    Semin Immunol; 2014 Jun; 26(3):183-90. PubMed ID: 24613728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
    Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
    J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.